Efficacy in SOOTHE, A Phase 2b Trial of BLU-5937 In Refractory Chronic Cough, Was Not Dependant of Taste Disturbance Adverse Events
S. Birring (London, United Kingdom), J. Smith (Manchester, United Kingdom), L. Mcgarvey (Belfast, United Kingdom), A. Morice (Cottingham, United Kingdom), A. Goldsobel (San Jose, United States), S. Lanouette (Montreal, Canada), R. Yang (Wilmington, United States), A. Levengood (Wilmington, United States), M. Garin (Wilmington, United States), C. Bonuccelli (Wilmington, United States)
Source: International Congress 2022 – Chronic cough, airway diseases and methods
Session: Chronic cough, airway diseases and methods
Session type: Thematic Poster
Number: 177
 
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. Birring (London, United Kingdom), J. Smith (Manchester, United Kingdom), L. Mcgarvey (Belfast, United Kingdom), A. Morice (Cottingham, United Kingdom), A. Goldsobel (San Jose, United States), S. Lanouette (Montreal, Canada), R. Yang (Wilmington, United States), A. Levengood (Wilmington, United States), M. Garin (Wilmington, United States), C. Bonuccelli (Wilmington, United States). Efficacy in SOOTHE, A Phase 2b Trial of BLU-5937 In Refractory Chronic Cough, Was Not Dependant of Taste Disturbance Adverse Events. 177
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|